RUBIUS THERAPEUTICS Item 5.07 - Submission of Matters to a Vote of Security Holders.
(i) To elect three Class III directors to the Company's board of directors, to serve until the 2024 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal; and
(ii) To ratify the appointment of
The proposals are described in detail in the Company's Proxy Statement filed
with the
The number of shares of common stock entitled to vote at the Annual Meeting was 81,230,888. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 72,438,370. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.
The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:
(a) Election of Class III Directors.
Director Nominee Votes For Votes Withheld Pablo J. Cagnoni, M.D. 61,348,312 1,604,715
61,328,894 1,624,133
There were 9,485,343 broker non-votes regarding the election of directors.
(b) Ratification of the appointment of
Company's independent registered public accounting firm for the fiscal year
ending December 31, 2021 .
Stockholders ratified the appointment of
© Edgar Online, source
